{"id":29352,"date":"2026-04-25T07:43:30","date_gmt":"2026-04-25T07:43:30","guid":{"rendered":"https:\/\/www.medicalbillersandcoders.com\/blog\/?post_type=wpseo_locations&p=29352"},"modified":"2026-04-26T07:45:57","modified_gmt":"2026-04-26T07:45:57","slug":"florida-dermatology-practice-capturing-dermatopathology-revenue","status":"publish","type":"wpseo_locations","link":"https:\/\/www.medicalbillersandcoders.com\/blog\/locations\/florida-dermatology-practice-capturing-dermatopathology-revenue\/","title":{"rendered":"Is Your Florida Dermatology Practice Capturing Dermatopathology Revenue Separately?"},"content":{"rendered":"

No \u2014 and for most Florida dermatology practices, dermatopathology revenue is either partially captured, incorrectly bundled, or structurally invisible within the billing infrastructure.<\/strong> The failure to capture dermatopathology revenue separately is not a coding oversight \u2014 it is a systemic billing architecture problem that compounds across every specimen processed, every payer adjudicated, and every month the correct TC\/PC split billing protocol is absent. A Florida dermatology practice processing 300\u2013500 biopsy specimens monthly and failing to capture dermatopathology revenue separately forfeits $180,000\u2013$420,000 annually \u2014 revenue that is fully legitimate, documentable, and recoverable with the correct RCM infrastructure in place.<\/p>\n

Capturing dermatopathology revenue separately requires operational precision across three distinct billing dimensions: the correct identification of which entity performs the technical component versus the professional component for each specimen; the correct application of TC and PC modifiers \u2014 or the global code \u2014 based on that entity determination; and the correct place-of-service coding that reflects where each component was performed, not where the specimen was collected.<\/p>\n

Florida dermatology practices that do not capture dermatopathology revenue separately across all three dimensions simultaneously are generating partial reimbursement at best and duplicate claim conflicts at worst \u2014 both of which produce revenue loss that the 90-Day AR Diagnostic quantifies with precision. The OIG has identified TC\/PC modifier misuse and failure to capture dermatopathology revenue separately as persistent improper payment risks in dermatology billing (OIG Work Plan, Dermatology Billing Practices<\/a>, 2024). Medical Billers and Coders structures all Dermatology Billing Services in Florida engagements around the operational framework required to capture dermatopathology revenue separately, accurately, and at full contractual value.<\/p>\n

\n

Why Florida Dermatology Practices Fail to Capture Dermatopathology Revenue Separately<\/h3>\n

1. The TC\/PC Split Is Not Operationalized in the Billing Workflow<\/strong><\/p>\n

The most fundamental reason Florida dermatology practices do not capture dermatopathology revenue separately is that the TC\/PC split is treated as a coding decision rather than a workflow architecture decision. In a correctly structured dermatopathology billing model, the split between technical and professional components is determined at the point of specimen intake \u2014 based on which entity owns the processing equipment, which entity employs the processing staff, and which entity employs or contracts the interpreting dermatopathologist.<\/p>\n

When this determination is not embedded in the specimen intake workflow as a structured data field, billing teams make ad hoc TC\/PC decisions at claim submission \u2014 producing inconsistent modifier application, global code conflicts, and systematic failure to capture dermatopathology revenue separately across high-volume specimen populations.<\/p>\n

For a Florida dermatology practice processing 400 specimens monthly with an average TC reimbursement of $42 under Medicare and $58 under commercial plans, failing to capture the TC separately on 60% of eligible claims produces $10,080\u2013$13,920 in monthly uncaptured revenue \u2014 $120,960\u2013$167,040 annually \u2014 from a single modifier decision point. Dermatology Billing Services in Florida must architect the TC\/PC determination as a specimen-level workflow event, not a claim-level coding choice.<\/p>\n

2. In-House vs. Reference Laboratory Billing Rights Are Not Contractually Defined<\/strong><\/p>\n

A Florida dermatology practice that sends specimens to a reference laboratory for processing cannot capture the TC separately \u2014 the reference laboratory holds the TC billing rights for work it performs. However, a practice that employs processing staff and owns laboratory equipment can and must capture the TC separately to recover the technical component revenue it is entitled to bill. The critical failure occurs when practices have mixed laboratory models \u2014 some specimens processed in-house, others sent to reference laboratories \u2014 and apply a uniform billing protocol across both categories. Capturing dermatopathology revenue separately in a mixed-model environment requires a specimen-level tracking system that assigns billing rights at the point of send-out determination.<\/p>\n

Florida Dermatology Billing Services<\/a> that lack this system either forfeit TC revenue on in-house specimens by submitting reference laboratory billing logic, or generate recoupment exposure on send-out specimens by billing TC claims the reference laboratory is simultaneously billing. The OIG has identified reference laboratory billing rights misassignment as a compliance risk under the Anti-Kickback Statute (42 U.S.C. \u00a7 1320a-7b).<\/p>\n

3. Ancillary Stain Revenue Is Bundled Rather Than Separately Captured<\/strong><\/p>\n

Capturing dermatopathology revenue separately extends beyond the base 88305 skin biopsy interpretation code to the ancillary staining procedures that complex specimens require. Immunohistochemistry stains (CPT 88342, 88344), special stains (CPT 88312, 88313), and electron microscopy (CPT 88348) are separately reimbursable \u2014 at $38\u2013$215 per procedure \u2014 when correctly unbundled from the base pathology code in compliance with CMS National Correct Coding Initiative (NCCI) edit logic. Florida dermatology practices that do not capture ancillary stain revenue separately bundle it into the 88305 global rate and forfeit the incremental reimbursement entirely. At 80\u2013120 complex specimens monthly requiring ancillary staining, the failure to capture stain revenue separately produces $36,480\u2013$154,800 in annual uncaptured revenue \u2014 a loss category that is invisible in standard denial reporting because no denial is generated; the stain simply is never billed.<\/p>\n

4. Place-of-Service Coding Prevents Separate Revenue Capture at the Adjudication Level<\/strong><\/p>\n

Even when Florida dermatology practices correctly apply TC and PC modifiers, they frequently fail to capture dermatopathology revenue separately at the payer adjudication level due to POS code errors. The technical component claim must reflect the POS of the processing laboratory \u2014 not the POS of the specimen collection site. A TC claim submitted with POS 11 (office) when processing occurred at a hospital-affiliated laboratory (POS 22) is adjudicated under the office-based fee schedule rather than the hospital outpatient rate \u2014 producing an 18\u201334% underpayment that represents partial, not full, separate revenue capture.<\/p>\n

Conversely, a TC claim submitted with POS 22 when processing occurred in the office triggers HOPPS bundling logic at certain payers, eliminating separate TC reimbursement entirely. POS miscoding is therefore a mechanism by which a Florida dermatology practice appears to be capturing dermatopathology revenue separately \u2014 because the claim is submitted and paid \u2014 while actually recovering only a fraction of the entitled reimbursement.<\/p>\n

5. Florida SMMC Plan Credentialing Gaps Block Separate TC Capture<\/strong><\/p>\n

Florida SMMC plans require that dermatology practices hold AHCA clinical laboratory licensure under Florida Statute \u00a7 483.051 as a condition of TC billing eligibility. Practices that hold CLIA certification but have not completed AHCA licensure cannot capture the technical component separately from SMMC plans \u2014 TC claims are denied on the first pass and classified as administrative denials rather than credentialing deficiencies. For Florida dermatology practices serving Medicaid-covered patient populations, the inability to capture dermatopathology revenue separately from SMMC plans eliminates TC revenue across an entire payer class until AHCA licensure is confirmed \u2014 a gap that the 90-Day AR Diagnostic identifies at the credentialing layer rather than the billing layer.<\/p>\n

\n

The 90-Day AR Diagnostic: Quantifying Separate Capture Failures<\/h3>\n

A 90-Day AR Diagnostic<\/strong> for Florida dermatology practices measures the gap between dermatopathology revenue that should be captured separately and what is actually being collected. It cross-references every processed specimen against the assigned TC\/PC billing model, the applied modifier, the submitted POS code, and the payment received \u2014 producing a separate capture rate by specimen type, payer, and billing component. Medical Billers and Coders apply the 90-Day AR Diagnostic as the mandatory entry point for all \u00a0engagements, establishing a baseline separate capture register before any RCM intervention is designed.<\/p>\n

Table 1: 90-Day AR Diagnostic \u2014 Separate Dermatopathology Revenue Capture Indicators<\/strong><\/p>\n

\n\n\n\n\n\n\n\n\n\n\n
Capture Metric<\/strong><\/td>\nBenchmark (Target)<\/strong><\/td>\nFlorida Dermatology 2026 Avg.<\/strong><\/td>\nLeakage Signal Threshold<\/strong><\/td>\nCorrective Action<\/strong><\/td>\n<\/tr>\n<\/thead>\n
TC Separate Capture Rate (Eligible Claims)<\/td>\n\u2265 97%<\/td>\n54\u201368%<\/td>\n< 80%<\/td>\nSpecimen-level TC\/PC workflow map<\/td>\n<\/tr>\n
PC Separate Capture Rate (Split Arrangements)<\/td>\n\u2265 97%<\/td>\n61\u201374%<\/td>\n< 85%<\/td>\nDermatopathologist billing protocol<\/td>\n<\/tr>\n
Ancillary Stain Separate Billing Rate<\/td>\n\u2265 95%<\/td>\n38\u201352%<\/td>\n< 75%<\/td>\nStain unbundling compliance tool<\/td>\n<\/tr>\n
POS Code Accuracy on TC Claims<\/td>\n\u2265 99%<\/td>\n74\u201383%<\/td>\n< 92%<\/td>\nPOS-to-lab location reconciliation<\/td>\n<\/tr>\n
SMMC TC Capture Rate<\/td>\n\u2265 94%<\/td>\n47\u201361%<\/td>\n< 80%<\/td>\nAHCA credentialing audit<\/td>\n<\/tr>\n
Net Dermatopathology NRY<\/td>\n\u2265 97%<\/td>\n79\u201386%<\/td>\n< 92%<\/td>\nFull-cycle dermatopathology RCM<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Source: CMS NCCI Edit Files 2026; OIG Dermatology Work Plan 2024; Florida AHCA Clinical Laboratory Policy; Medical Billers and Coders analytics.<\/em><\/p>\n

\n

Florida Payer-Specific Barriers to Separate Dermatopathology Revenue Capture<\/h3>\n

Florida’s payer environment introduces plan-specific barriers to capturing dermatopathology revenue separately that do not exist uniformly across the national billing landscape. Florida Blue implemented a January 2026 policy requiring prior notification for in-office laboratory TC billing on split arrangements \u2014 a requirement that blocks separate TC capture for practices that have not integrated the notification step into their pre-submission workflow. Aetna and Cigna Florida apply commercial NCCI edit override logic that prevents separate ancillary stain capture on claim combinations that CMS permits \u2014 requiring payer-specific stain bundling maps rather than a single NCCI compliance framework. Florida Medicaid SMMC plans introduced 2026 prior authorization thresholds for TC claims exceeding four specimens per date of service \u2014 meaning practices that routinely process five or more specimens per encounter must obtain authorization before separate TC capture is possible on the over-threshold specimens.<\/p>\n

Table 2: Florida Payer Barriers to Separate Dermatopathology Revenue Capture \u2014 2026<\/strong><\/p>\n

\n\n\n\n\n\n\n\n\n\n
Payer<\/strong><\/td>\nBarrier to Separate Capture<\/strong><\/td>\nRevenue Impact Per Claim<\/strong><\/td>\nDetection Method<\/strong><\/td>\nResolution<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Florida Blue<\/td>\nTC split prior notification (2026 policy)<\/td>\n$54<\/td>\nContract policy audit<\/td>\nPre-submission notification workflow<\/td>\n<\/tr>\n
Aetna Florida<\/td>\nCommercial NCCI override \u2014 IHC stains<\/td>\n$112<\/td>\nPayer edit vs. CMS NCCI comparison<\/td>\nClinical edit appeal protocol<\/td>\n<\/tr>\n
Cigna Florida<\/td>\nStain unbundling commercial edit conflict<\/td>\n$98<\/td>\nEdit mapping by procedure pair<\/td>\nMedical necessity appeal<\/td>\n<\/tr>\n
Florida Medicaid SMMC<\/td>\nPA threshold \u2014 4+ specimens per DOS<\/td>\n$143<\/td>\nAuth gap tracking by DOS<\/td>\nPA workflow for high-volume DOS<\/td>\n<\/tr>\n
Medicare Advantage (FL)<\/td>\nGlobal bill conflict on split arrangements<\/td>\n$187<\/td>\nTC\/PC conflict audit by claim<\/td>\nBilling model structural correction<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Source: Florida Blue Policy Update January 2026; CMS NCCI Edit Files 2026; Florida AHCA SMMC Contract 2026; Medical Billers and Coders payer analytics.<\/em><\/p>\n

\n

Full-Cycle RCM Infrastructure: Capturing Dermatopathology Revenue Separately at Scale<\/h3>\n

Building the infrastructure to capture dermatopathology revenue separately across all specimen types, billing models, and payer classes requires five concurrent operational capabilities \u2014 not sequential billing corrections. First, a specimen-level TC\/PC determination workflow embedded in the specimen intake process \u2014 assigning billing model, modifier requirement, and billing rights ownership before the specimen reaches the laboratory, not after the claim is generated. Second, a reference laboratory send-out tracking system that records billing rights assignment at the point of send-out decision and prevents TC claim submission on specimens for which the reference laboratory holds billing rights. Third, an ancillary stain capture protocol that flags complex specimens for stain unbundling review at charge entry \u2014 applying NCCI edit logic and payer-specific commercial edit rules simultaneously to maximize separate stain revenue capture without generating edit denials. Fourth, a POS validation step in the pre-submission claim scrubbing workflow that confirms processing site POS on every TC claim before adjudication. Fifth, a Florida SMMC credentialing compliance register that verifies AHCA licensure status before TC claims are submitted to any SMMC plan \u2014 updated at each credentialing cycle and AHCA policy update.<\/p>\n

Net Revenue Yield (NRY)<\/strong> \u2014 target \u2265 97% \u2014 and Total Cost of Collection (TCC)<\/strong> \u2014 target $0.06\u2013$0.09 per dollar collected \u2014 anchor all dermatopathology billing performance measurement. Florida dermatology practices not capturing dermatopathology revenue separately are tracking NRY in the 79\u201386% range \u2014 an 11\u201318 percentage point gap from target. Medical Billers and Coders measures both benchmarks at 30-day intervals across all Medical Billing Services in Florida<\/a> dermatology engagements, with separate capture rate tracked as a discrete performance metric alongside NRY and TCC.<\/p>\n

Table 3: Full-Cycle RCM \u2014 Separate Dermatopathology Revenue Capture Implementation Map<\/strong><\/p>\n

\n\n\n\n\n\n\n\n\n\n\n
RCM Component<\/td>\nCurrent Failure State<\/td>\nIntervention<\/td>\nExpected Annual Revenue Recovery<\/td>\n<\/tr>\n<\/thead>\n
Specimen Intake Workflow<\/td>\nTC\/PC determined at claim submission<\/td>\nSpecimen-level TC\/PC assignment at intake<\/td>\n$55,000\u2013$118,000<\/td>\n<\/tr>\n
Reference Lab Billing Rights<\/td>\nTC billed on reference lab specimens<\/td>\nSend-out billing rights tracking system<\/td>\n$42,000\u2013$86,000<\/td>\n<\/tr>\n
Ancillary Stain Capture<\/td>\nStain revenue bundled into 88305<\/td>\nStain unbundling compliance + NCCI tool<\/td>\n$36,000\u2013$154,000<\/td>\n<\/tr>\n
POS Validation<\/td>\nCollection site POS on TC claims<\/td>\nPre-submission POS reconciliation<\/td>\n$38,000\u2013$74,000<\/td>\n<\/tr>\n
SMMC Credentialing<\/td>\nTC denied for AHCA licensure gap<\/td>\nAHCA licensure audit + registration<\/td>\n$18,000\u2013$42,000<\/td>\n<\/tr>\n
Total Separate Capture Recovery<\/strong><\/td>\nAll dermatopathology capture failures<\/strong><\/td>\nFull separate capture RCM program<\/strong><\/td>\n$189,000\u2013$474,000<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Source: CMS NCCI Edit Files 2026; Florida AHCA Laboratory Credentialing Policy; Medical Billers and Coders dermatopathology RCM data.<\/em><\/p>\n

\n

Frequently Asked Questions<\/h3>\n

Q1. What does it mean for a Florida dermatology practice to capture dermatopathology revenue separately, and why does it require a structural approach?<\/strong><\/p>\n

Capturing dermatopathology revenue separately means billing the technical component (TC) and professional component (PC) of pathology services as distinct claim events \u2014 each reflecting the correct performing entity, modifier, and place of service \u2014 rather than bundling both components into an undifferentiated global charge or allowing one component to go unbilled. It requires a structural approach because the determination of which entity bills which component must be made at the specimen intake level \u2014 before processing occurs \u2014 and must be enforced consistently across every specimen, every payer, and every billing cycle. Ad hoc TC\/PC decisions at the claim submission stage produce inconsistent results that generate both revenue loss and compliance exposure simultaneously.<\/p>\n

Q2. How does a Florida dermatology practice determine whether it is eligible to capture the TC separately?<\/strong><\/p>\n

Eligibility to capture the TC separately depends on three conditions being met simultaneously: the practice must own or lease the laboratory processing equipment; the practice must employ the staff performing the technical processing; and the practice must hold both CLIA certification and AHCA clinical laboratory licensure under Florida Statute \u00a7 483.051. If any of these conditions is not met \u2014 including the AHCA licensure requirement that CLIA certification alone does not satisfy \u2014 the practice is not eligible to capture the TC separately from Florida SMMC plans and faces recoupment exposure if TC claims have been submitted without licensure eligibility.<\/p>\n

Q3. What is the annual revenue impact of failing to capture ancillary stain revenue separately in a high-volume Florida dermatology practice?<\/strong><\/p>\n

For a Florida dermatology practice processing 80\u2013120 complex specimens monthly that require ancillary staining \u2014 IHC stains at $78\u2013$215 per procedure and special stains at $38\u2013$96 per procedure \u2014 the failure to capture stain revenue separately produces $36,480\u2013$154,800 in annual uncaptured revenue. This loss is structurally invisible in standard denial reporting because no claim is submitted and no denial is generated \u2014 the stain revenue simply is never billed. The 90-Day AR Diagnostic identifies this gap by cross-referencing complex specimen pathology reports against submitted claim lines, flagging specimens where ancillary staining is documented in the pathology report but absent from the billing record.<\/p>\n

Q4. How does Florida Blue’s 2026 prior notification requirement affect separate TC revenue capture for split billing arrangements?<\/strong><\/p>\n

Florida Blue’s January 2026 policy requires that dermatology practices provide prior notification to the plan before billing TC claims on split arrangements where the professional component is performed by a separately contracted dermatopathologist. Practices that submit TC claims without prior notification have those claims denied on the first pass \u2014 not as a TC\/PC conflict, but as a prior notification failure. Because the denial code does not reference TC\/PC billing model errors, Dermatology Billing Services in Florida frequently misclassify these denials as administrative and write them off rather than identifying the policy change as the root cause and implementing the notification step. The 90-Day AR Diagnostic identifies the Florida Blue prior notification denial pattern by isolating the denial code frequency against the date the policy took effect.<\/p>\n

Q5. What benchmark should Florida dermatology practices use to evaluate whether they are capturing dermatopathology revenue separately at an acceptable rate?<\/strong><\/p>\n

The target TC separate capture rate for eligible claims is \u2265 97% \u2014 meaning that 97% or more of specimens for which the practice holds TC billing rights generate a submitted TC claim at the correct rate, with the correct modifier, and at the correct POS. Florida dermatology practices currently average 54\u201368% TC separate capture on eligible claims \u2014 a 29\u201343 percentage point gap from benchmark that represents the primary quantifiable target of the 90-Day AR Diagnostic. The PC separate capture rate on split billing arrangements should similarly reach \u2265 97%, and ancillary stain separate billing rate should reach \u2265 95%. Practices operating below these thresholds across all three capture dimensions are forfeiting $189,000\u2013$474,000 in annual recoverable dermatopathology revenue.<\/p>\n

\n

References<\/h3>\n